Viking Therapeutics Reports Clinical Progress and Financial Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Source: PRnewswire
Viking Therapeutics Inc. saw its stock surge by 18.18% as it reached a 5-day high, reflecting positive market sentiment following recent financial and clinical updates.
The company reported a significant increase in R&D expenses for Q4 2025, totaling $153.5 million, driven by ongoing clinical trials for its obesity treatment VK2735. Despite a widening net loss of $157.7 million, Viking's completion of enrollment for the VANQUISH-1 trial and progress towards the VANQUISH-2 trial indicate strong commitment to advancing its drug pipeline. This strategic focus on obesity treatment is expected to enhance market recognition and potential revenue.
With a cash reserve of $706 million, Viking is well-positioned to support its R&D activities and navigate the financial challenges posed by increased expenditures. The company's proactive approach in clinical development and market strategy suggests a promising outlook for its obesity treatment initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.190
Low
70.00
Averages
97.00
High
125.00
Current: 32.190
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Is It Time to Reload Your Underinvested Portfolio?
- Shopify Stock Fluctuations: Shopify's stock has dropped 40% since last October, currently valued at $154 billion; despite pressures from slowing sales growth and rising interest rates, its Q1 revenue growth rate of 34% highlights its significance in the future of e-commerce.
- Nice's Customer Service Technology: Nice Ltd, with a market cap of $5.4 billion, derives only 14% of its cloud revenue from AI, yet its Q1 recurring revenue grew 66% year-over-year, showcasing its strong performance and growth potential in the customer service market.
- Viking Therapeutics' Drug Development: Viking Therapeutics is conducting phase 3 trials for its GLP-1 weight-loss drug VK2735, currently valued at $3.8 billion; analysts unanimously rate its stock as a strong buy with a target price of $95.40, reflecting confidence in its market potential.
- Investor Focus on Emerging Stocks: Despite overall market volatility, investor interest in Shopify, Nice, and Viking indicates optimism towards these growth stocks, particularly in the long-term growth prospects within the e-commerce and health sectors.
See More
Analysis of Shopify's Stock Price Decline
- Shopify's Stock Decline: Shopify's shares have fallen 40% since October, driven by slowing sales growth, rising interest rates, and potential threats from AI, although these concerns may be overstated.
- Nice Ltd's Customer Service Edge: Nice Ltd's platform facilitates over 20 billion interactions annually, and while AI accounts for only 14% of its cloud revenue, its annualized revenue has reached $345 million, indicating strong growth potential.
- Viking Therapeutics' Market Potential: Viking Therapeutics' VK2735 is in phase 3 trials and could disrupt the $200 billion obesity drug market, with analysts setting a target price of $95.40, representing a 200% upside from current levels.
- Cautious Investor Sentiment: Despite stocks remaining above late-March lows, many investors are on the sidelines due to concerns about a market pullback, particularly in the current economic climate, which challenges confidence in reinvesting.
See More
Truist Initiates Coverage on VKTX with Buy Rating and $83 Price Target
- Analyst Rating Boost: Truist has initiated coverage on Viking Therapeutics (VKTX) with a ‘Buy’ rating and an $83 price target, indicating a potential upside of 162% from current levels, reflecting strong market confidence in its growth prospects.
- Weight Loss Market Dynamics: Eli Lilly (LLY) saw its stock price climb nearly 25% over the past month, making it the strongest performer among major obesity drug stocks, highlighting investor recognition of its sustained demand for GLP-1 therapies and market leadership.
- Viking's Competitive Edge: Truist emphasized that Viking's VK2735 drug achieved a 14.7% weight loss in just 13 weeks, with patients continuing to lose weight, showcasing its differentiated competitive advantage in the obesity drug market that could attract more patients.
- Lilly's Market Expansion: Lilly recently announced deals worth up to $3.8 billion with three vaccine developers, further expanding its footprint in infectious diseases and long-term healthcare infrastructure, indicating growth potential beyond its obesity drug portfolio.
See More
Obesity Drug Market Poised for Growth
- Market Potential: The obesity drug market is projected to reach nearly $100 billion by 2030, prompting significant investor interest and confidence, which could lead to substantial stock price increases for companies in this sector.
- Viking Therapeutics Progress: Viking Therapeutics is conducting phase 3 trials for VK-2735, with promising early results suggesting potential market success; strong data could drive stock prices higher, enhancing the company's competitive position in obesity treatment.
- AbbVie's Strategic Development: AbbVie is studying a long-acting amylin analog, with early trials indicating weight loss of 7% to 9%, which could add significant growth potential to its portfolio and strengthen its market position if successfully commercialized.
- Investor Optimism: As demand for obesity drugs rises, the potential success of Viking and AbbVie may attract more investor attention, driving stock prices up, especially against a backdrop of increasing market expectations for new therapies.
See More
Weight Loss Drug Market Poised for Growth
- Market Potential: Analysts predict the weight loss drug market could reach nearly $100 billion in the coming years, attracting significant investment into pharma and biotech companies, indicating strong growth prospects in this sector.
- Viking Therapeutics Progress: Viking Therapeutics is conducting phase 3 trials for VK-2735, with promising early results suggesting it could carve out a niche in the weight loss market, and strong data could drive the stock price higher again.
- AbbVie's New Strategy: AbbVie is studying a long-acting amylin analog, with early trials showing weight loss of 7% to 9%, which could add significant growth potential to its product portfolio if successful.
- Investment Opportunity Analysis: AbbVie’s price-to-earnings ratio is currently at 15 times, down from over 24 times a few months ago, indicating substantial room for stock price appreciation, with potential for doubling in the near future.
See More
Viking Therapeutics Faces Competitive Pressures
- Intensifying Market Competition: Viking Therapeutics' weight-loss candidate VK2735 showed promising results in clinical trials, but increasing competition from new product launches by Eli Lilly and Novo Nordisk may impact Viking's market share significantly.
- Dramatic Stock Price Decline: Viking's stock price has plummeted from nearly $100 to below $30, reflecting investor pessimism regarding its future prospects, particularly in light of stronger competitors entering the market.
- Cash Burn Risks: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face dilution risks if it fails to raise additional funds soon, further undermining investor confidence.
- Slow Clinical Progress: Although VK2735 remains in clinical trials, competitors are advancing in drug development, potentially placing Viking at a disadvantage in the market and affecting its long-term growth potential.
See More
Is It Time to Reload Your Underinvested Portfolio?
- Shopify Stock Fluctuations: Shopify's stock has dropped 40% since last October, currently valued at $154 billion; despite pressures from slowing sales growth and rising interest rates, its Q1 revenue growth rate of 34% highlights its significance in the future of e-commerce.
- Nice's Customer Service Technology: Nice Ltd, with a market cap of $5.4 billion, derives only 14% of its cloud revenue from AI, yet its Q1 recurring revenue grew 66% year-over-year, showcasing its strong performance and growth potential in the customer service market.
- Viking Therapeutics' Drug Development: Viking Therapeutics is conducting phase 3 trials for its GLP-1 weight-loss drug VK2735, currently valued at $3.8 billion; analysts unanimously rate its stock as a strong buy with a target price of $95.40, reflecting confidence in its market potential.
- Investor Focus on Emerging Stocks: Despite overall market volatility, investor interest in Shopify, Nice, and Viking indicates optimism towards these growth stocks, particularly in the long-term growth prospects within the e-commerce and health sectors.
See More
Analysis of Shopify's Stock Price Decline
- Shopify's Stock Decline: Shopify's shares have fallen 40% since October, driven by slowing sales growth, rising interest rates, and potential threats from AI, although these concerns may be overstated.
- Nice Ltd's Customer Service Edge: Nice Ltd's platform facilitates over 20 billion interactions annually, and while AI accounts for only 14% of its cloud revenue, its annualized revenue has reached $345 million, indicating strong growth potential.
- Viking Therapeutics' Market Potential: Viking Therapeutics' VK2735 is in phase 3 trials and could disrupt the $200 billion obesity drug market, with analysts setting a target price of $95.40, representing a 200% upside from current levels.
- Cautious Investor Sentiment: Despite stocks remaining above late-March lows, many investors are on the sidelines due to concerns about a market pullback, particularly in the current economic climate, which challenges confidence in reinvesting.
See More
Truist Initiates Coverage on VKTX with Buy Rating and $83 Price Target
- Analyst Rating Boost: Truist has initiated coverage on Viking Therapeutics (VKTX) with a ‘Buy’ rating and an $83 price target, indicating a potential upside of 162% from current levels, reflecting strong market confidence in its growth prospects.
- Weight Loss Market Dynamics: Eli Lilly (LLY) saw its stock price climb nearly 25% over the past month, making it the strongest performer among major obesity drug stocks, highlighting investor recognition of its sustained demand for GLP-1 therapies and market leadership.
- Viking's Competitive Edge: Truist emphasized that Viking's VK2735 drug achieved a 14.7% weight loss in just 13 weeks, with patients continuing to lose weight, showcasing its differentiated competitive advantage in the obesity drug market that could attract more patients.
- Lilly's Market Expansion: Lilly recently announced deals worth up to $3.8 billion with three vaccine developers, further expanding its footprint in infectious diseases and long-term healthcare infrastructure, indicating growth potential beyond its obesity drug portfolio.
See More
Obesity Drug Market Poised for Growth
- Market Potential: The obesity drug market is projected to reach nearly $100 billion by 2030, prompting significant investor interest and confidence, which could lead to substantial stock price increases for companies in this sector.
- Viking Therapeutics Progress: Viking Therapeutics is conducting phase 3 trials for VK-2735, with promising early results suggesting potential market success; strong data could drive stock prices higher, enhancing the company's competitive position in obesity treatment.
- AbbVie's Strategic Development: AbbVie is studying a long-acting amylin analog, with early trials indicating weight loss of 7% to 9%, which could add significant growth potential to its portfolio and strengthen its market position if successfully commercialized.
- Investor Optimism: As demand for obesity drugs rises, the potential success of Viking and AbbVie may attract more investor attention, driving stock prices up, especially against a backdrop of increasing market expectations for new therapies.
See More
Weight Loss Drug Market Poised for Growth
- Market Potential: Analysts predict the weight loss drug market could reach nearly $100 billion in the coming years, attracting significant investment into pharma and biotech companies, indicating strong growth prospects in this sector.
- Viking Therapeutics Progress: Viking Therapeutics is conducting phase 3 trials for VK-2735, with promising early results suggesting it could carve out a niche in the weight loss market, and strong data could drive the stock price higher again.
- AbbVie's New Strategy: AbbVie is studying a long-acting amylin analog, with early trials showing weight loss of 7% to 9%, which could add significant growth potential to its product portfolio if successful.
- Investment Opportunity Analysis: AbbVie’s price-to-earnings ratio is currently at 15 times, down from over 24 times a few months ago, indicating substantial room for stock price appreciation, with potential for doubling in the near future.
See More
Viking Therapeutics Faces Competitive Pressures
- Intensifying Market Competition: Viking Therapeutics' weight-loss candidate VK2735 showed promising results in clinical trials, but increasing competition from new product launches by Eli Lilly and Novo Nordisk may impact Viking's market share significantly.
- Dramatic Stock Price Decline: Viking's stock price has plummeted from nearly $100 to below $30, reflecting investor pessimism regarding its future prospects, particularly in light of stronger competitors entering the market.
- Cash Burn Risks: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face dilution risks if it fails to raise additional funds soon, further undermining investor confidence.
- Slow Clinical Progress: Although VK2735 remains in clinical trials, competitors are advancing in drug development, potentially placing Viking at a disadvantage in the market and affecting its long-term growth potential.
See More
